Comparison of continuation rates with three TNF alpha antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Joint Bone Spine Année : 2016

Comparison of continuation rates with three TNF alpha antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study

(1) , (2) , , (3, 4) , (4, 5) , (6)
1
2
3
4
5
6
Fichier non déposé

Dates et versions

hal-03564084 , version 1 (10-02-2022)

Identifiants

Citer

Benjamin Batteux, Agathe Devauchelle, Pauline Lasselin Boyard, Alice Sejourne, Patrice Fardellone, et al.. Comparison of continuation rates with three TNF alpha antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study. Joint Bone Spine, 2016, 83 (5), pp.607-609. ⟨10.1016/j.jbspin.2016.01.005⟩. ⟨hal-03564084⟩
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More